MiMedx Group Inc (MDXG)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $468.42M
Last updated: Nov 17, 2026 at 11:05 AM ET
MiMedx Group Inc (MDXG) Financials: Revenue, Profit and Cash Flow
MiMedx Group reported revenue of $418.63M for the fiscal year ended Dec 31, 2025, up 20.0% from the year before. That year, net income was $48.58M with a net margin of 11.6%, operating cash flow was $74.00M and free cash flow was $72.97M. The quarter ended Sep 30, 2026 had revenue of $62.28M and net income of -$8.68M.
Revenue and Margins
The operating margin was 15.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $221.71M, a compound annual rate of 7.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $418.63M | +20.0% | 82.6% | 15.3% | 11.6% |
| Dec 2024 | $348.88M | +8.5% | 82.8% | 16.9% | 12.2% |
| Dec 2023 | $321.48M | +20.0% | 83.0% | 11.5% | 18.1% |
| Dec 2022 | $267.84M | +10.7% | 82.0% | -5.5% | -11.3% |
| Dec 2021 | $242.02M | -2.5% | 83.6% | -2.9% | -4.2% |
| Dec 2020 | $248.23M | -17.0% | 84.2% | -18.3% | -19.9% |
| Dec 2019 | $299.25M | -16.7% | 85.6% | -7.1% | -8.5% |
| Dec 2018 | $359.11M | +11.8% | 89.9% | -1.1% | -8.3% |
| Dec 2017 | $321.14M | +44.8% | 89.0% | 14.4% | 20.2% |
| Dec 2016 | $221.71M | N/A | 86.0% | 0.4% | 0.2% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 14.5% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $418.63M | $348.88M | $321.48M | $267.84M | $242.02M | $248.23M | $299.25M | $359.11M | $321.14M | $221.71M |
| Cost of revenue | $73.01M | $60.07M | $54.63M | $48.32M | $39.63M | $39.33M | $43.08M | $36.39M | $35.22M | $30.94M |
| Gross profit | $345.62M | $288.81M | $266.84M | $219.53M | $202.39M | $208.90M | $256.17M | $322.73M | $285.92M | $190.77M |
| Research and development | $15.10M | $12.34M | $12.66M | $12.70M | $9.93M | $11.71M | $11.14M | $15.77M | $17.90M | $14.34M |
| Operating income | $63.89M | $58.87M | $37.12M | -$14.73M | -$7.05M | -$45.40M | -$21.16M | -$3.92M | $46.22M | $884.00K |
| Net income | $48.58M | $42.42M | $58.23M | -$30.20M | -$10.29M | -$49.28M | -$25.58M | -$29.98M | $64.73M | $390.00K |
| EBITDA | $78.21M | $64.34M | $40.52M | -$10.69M | -$836.00K | -$36.27M | -$11.86M | $2.94M | $51.10M | $6.17M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.28M | $64.36M | $58.99M | $118.09M | $113.72M | $98.61M | $88.20M | $92.91M | $84.06M | $87.21M | $84.71M | $86.83M |
| Gross profit | $49.70M | $44.38M | $41.62M | $99.04M | $95.01M | $79.92M | $71.65M | $76.00M | $68.73M | $72.35M | $71.72M | $72.99M |
| Operating income | -$11.70M | -$18.47M | -$16.05M | $21.08M | $22.19M | $12.37M | $8.25M | $11.05M | $11.16M | $23.45M | $13.20M | $15.49M |
| Net income | -$8.68M | -$14.84M | -$10.86M | $15.19M | $16.75M | $9.62M | $7.02M | $7.44M | $8.10M | $17.63M | $9.26M | $53.48M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $17.97M by $148.15M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $342.65M | $263.92M | $239.05M | $171.43M | $187.93M | $202.03M | $167.17M | $122.84M | $121.25M | $117.27M |
| Current assets | $277.47M | $191.89M | $164.26M | $134.20M | $148.52M | $160.62M | $123.25M | $74.05M | $48.75M | $59.47M |
| Cash and equivalents | $166.12M | $104.42M | $82.00M | $65.95M | $87.08M | $95.81M | $69.07M | $45.12M | $27.48M | $30.32M |
| Total liabilities | $86.11M | $70.81M | $96.33M | $96.92M | $95.35M | $110.61M | $132.77M | $73.19M | $47.46M | $69.21M |
| Short-term debt | $1.50M | $1.00M | $1.00M | $1.44M | $1.25M | $1.18M | $3.75M | $0 | N/A | $31.00K |
| Long-term debt | $16.47M | $17.83M | $48.10M | $48.59M | $48.13M | $47.70M | $61.91M | $0 | N/A | $2.00K |
| Shareholder equity | $256.55M | $193.11M | $142.72M | -$17.99M | $82.00K | -$150.00K | $34.40M | $49.66M | $73.80M | $48.07M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $264.55M | $281.00M | $308.68M | $342.65M | $318.99M | $291.11M | $270.42M | $263.92M | $243.89M | $230.18M | $221.68M | $239.05M |
| Total liabilities | $53.47M | $65.00M | $65.74M | $86.11M | $80.04M | $74.48M | $67.64M | $70.81M | $62.88M | $62.14M | $65.95M | $96.33M |
| Cash and equivalents | $120.79M | $135.84M | $159.77M | $166.12M | $142.08M | $118.87M | $106.43M | $104.42M | $88.80M | $69.04M | $48.49M | $82.00M |
| Shareholder equity | $211.08M | $216.00M | $242.94M | $256.55M | $238.95M | $216.62M | $202.78M | $193.11M | $181.01M | $168.04M | $155.73M | $142.72M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 98.6% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $74.00M | $66.20M | $26.77M | -$17.89M | -$1.98M | -$30.26M | -$39.41M | $35.80M | $62.94M | $23.85M |
| Capital expenditures | $1.03M | $1.68M | $1.99M | $1.51M | $3.22M | $4.23M | $1.75M | $9.42M | $5.13M | $6.21M |
| Free cash flow | $72.97M | $64.52M | $24.79M | -$19.41M | -$5.20M | -$34.49M | -$41.16M | $26.38M | $57.81M | $17.64M |
| Dividends paid | N/A | N/A | $997.00K | $651.00K | $1.44M | $100.00M | N/A | N/A | N/A | $0 |
| Share repurchases | $0 | $0 | $9.52M | $0 | $0 | $7.47M | $0 | $7.57M | $68.26M | $10.38M |
| Investing cash flow | -$6.89M | -$9.58M | -$2.15M | -$2.66M | -$3.40M | -$4.55M | $504.00K | -$9.22M | -$5.40M | -$11.68M |
| Financing cash flow | -$5.41M | -$34.20M | -$8.57M | -$580.00K | -$3.35M | $61.56M | $62.86M | -$8.93M | -$60.39M | -$8.15M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.92M | -$10.02M | $1.88M | $24.96M | $29.33M | $14.42M | $5.30M | $18.78M | $19.62M | $21.81M | $5.98M | $10.26M |
| Capital expenditures | $166.00K | $598.00K | $570.00K | $285.00K | $192.00K | $179.00K | $377.00K | $263.00K | $171.00K | $105.00K | $1.14M | $427.00K |
| Free cash flow | $3.75M | -$10.61M | $1.31M | $24.67M | $29.14M | $14.24M | $4.92M | $18.52M | $19.45M | $21.71M | $4.83M | $9.83M |
Frequently Asked Questions About MDXG
What is MiMedx Group's annual revenue?
MiMedx Group reported revenue of $418.63M for the fiscal year ended Dec 31, 2025.
How fast is MiMedx Group's revenue growing?
Revenue was up 20.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 16.1%.
Is MiMedx Group profitable?
Yes. MiMedx Group reported net income of $48.58M for the fiscal year ended Dec 31, 2025, with a net margin of 11.6%.
How much free cash flow does MDXG generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $74.00M minus capital expenditures of $1.03M produced free cash flow of $72.97M.
How much debt does MiMedx Group have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $16.47M, short-term debt of $1.50M and cash and equivalents of $166.12M.
MDXG pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors